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Abstract: Oxidized metabolites of dopamine known as dopamine quinone derivatives are 
thought to play a pivotal role in the degeneration of nigrostriatal dopaminergic neurons in 
Parkinson’s disease. Although such quinone derivatives are usually produced via the 
autoxidation of catecholamines, tyrosinase, which is a key enzyme in melanin biosynthesis 
via the production of DOPA and subsequent molecules, can potentially accelerate the 
induction of catecholamine quinone derivatives by its oxidase activity. We have developed 
neuronal cell lines in which the expression of human tyrosinase was inducible. 
Overexpression of tyrosinase resulted in increased intracellular dopamine content in 
association with the formation of melanin pigments in neuronal somata, which eventually 
causes apoptotic cell death. This cellular model will provide a useful tool for detailed 
analyses of the neurotoxicity of oxidized catechol metabolites. 
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1. Introduction 
Parkinson's disease is a progressive neurodegenerative disorder characterized by the selective 
degeneration of dopamine (DA)-containing pigmented neurons mainly located in the substantia nigra. 
Neuromelanin-containing neurons are particularly susceptible to degeneration and their 
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depigmentation is the hallmark of the advanced disease. The proposed mechanisms underlaying the 
pathogenesis and progression of neurodegeneration in the substantia nigra include iron-catalyzed 
oxidative stress, mitochondrial dysfunctions, inflammation and disturbances of protein 
metabolism [1–3]. DA itself can be autoxidized to form reactive species, DA quinone, which may be 
covalently incorporated into a variety of molecules including proteins, lipids, and nucleic acids [4–8]. 
In addition, highly reactive oxygen species (ROS; hydrogen peroxide, superoxide radical, and 
hydroxyl radical) are generated, not only in catecholamine oxidation, but also during the decay of 
redox-active quinones [9]. Several targets have been identified for these catechol quinones in neurons. 
In the cytosol, DA quinone can react with the sulfhydryl group of cysteine residues to form protein 
adducts, thus leading to irreversible alteration of protein function. DA oxidation inhibits DA 
transporter glutamate transporter, and mitochondrial respiratory chain function [10]. Furthermore, DA 
quinone can interact with -synuclein, a protein responsible for familial Parkinson's disease [11], and 
form a toxic intermediate in nigral cells [12]. At physiological pH DA quinone cyclizes irreversibly 
and spontanenously to form dopaminochrome (also celled aminochrome) and it is a precursor of 
neuromelanin. Such one-electron reduction of DA quinone is potentially neurotoxic and it has been 
reported that aminochrome is the metabolite of DA oxidation involved in the formation of -synuclein 
adducts inducing and stabilizing cytotoxic protofibrils [13,14]. These findings suggest that DA-derived 
reactive species may interact with some key molecules in neuronal cells, thereby leading to neuronal 
cell death and the concomitant neuropathological changes.   
Tyrosinase (EC 1.14.18.1; monophenol monooxygenase), a copper-containing metalloprotein, is a 
key enzyme in the biosynthesis of melanins and other polyphenolic compounds [15].  Tyrosinase 
catalyzes both the hydroxylation of tyrosine to L-DOPA and the subsequent oxidation of L-DOPA to 
dopaquinone (Figure 1) [16,17]. In addition, under certain circumstances tyrosinase may oxidize DA to 
form melanin pigments, probably through DA quinone  [18,19]. Therefore, tyrosinase is the major 
enzyme required for the synthesis of melanin in skin and hair and may contribute to neuromelanin 
formation. In mammals, tyrosinase is specifically expressed in differentiated melanin-producing cells 
such as melanocytes that are distributed in the skin and retinal pigment epithelium [20]. In the 
mammalian central nervous system, a DA-derived pigment, neuromelanin, is found in nigral 
dopaminergic cells [21]. The existence of tyrosinase in the central nervous system is still controversial, 
although several studies have shown the expression of tyrosinase gene, its protein, and its catalytic 
activity in the nigral neurons [18,22–24]. Greggio et al has shown that tyrosinase activity is higher in 
substantia nigra, a region rich in DA, the major tyrosinase substrate.   
To obtain better understanding of the potential toxicity of oxidized dopamine metabolites in 
pigmented neuronal cells, we established neuronal cell lines that express human tyrosinase in response 
to doxycycline, an exogenous inducer [25–28]. Tyrosinase induction leads to apoptotic cell death in 
concomitant with the increased production of intracellular DA and ROS, followed by the formation of 
pigmented granules mimicking those containing neuromelanin that are seen in nigral cells. Int. J. Mol. Sci. 2010, 11              
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Figure 1. Generation of cytotoxic catechol o-quinones and other reactive oxygen species 
during the enzymatic action of tyrosinase. 
 
2. Establishment of Neuronal Cell Lines Inducible for the Expression of Human Tyrosinase 
We used the T-REx tetracycline-regulatable gene expression system (Invitrogen, Carlsbad, CA, 
USA) to induce human tyrosinase in dopaminergic SH-SY5Y neuronal cells. To generate the 
expression construct of human tyrosinase (pcDNA4(TO)-tyrosinase), human tyrosinase cDNA was 
cloned at XhoI/XbaI sites in the mamalian expression vector pcDNA4(TO). Tet-repressor protein was 
encoded by the pcDNA6/TR regulatory vector. Stable SH-SY5Y neuroblastoma cell lines expressing 
human tyrosinase under the transcriptional control of the T-REx system were then cloned by 
successive expression of the hybrid Tet repressor and pcDNA4(TO)-tyrosiase under the existence of 
selection antibiotics. In the absence of doxycycline, the expression of tyrosinase was repressed by the 
binding of Tet-repressor homodimers to the tetracycline operator sites in the pcDNA4(TO)-tyrosinase. 
The addition of doxycycline (1 g/mL) resulted in a derepression of promoter activity, leading to 
expression of the tyrosinase protein. Three days after the doxycycline induction, the tyrosinase protein 
as well as intracellular ROS had accumulated in cytoplasmic granules that exhibited cobblestone-like 
pigmented structures similar to the neuromelanin granules seen in nigral cells (Figure 2).   
For proper melanogenesis in pigment cells, tyrosinase should be N-glycosylated in the endoplasmic 
reticulum (ER), modified further in the Golgi apparatus and then translocated into melanosomes   
[29,30]. During these processes, the interaction of tyrosinase with the ER chaperone calnexin is 
indispensable for the protein folding  [31]. We confirmed that ER marker calnexin surrounded the 
assembled tyrosinase, suggesting the proper interaction of these two molecules. In addition, the 
tyrosinase-containing structures were co-stained with the lysosomal marker LysoTracker, suggesting 
that the expressed tyrosinase was targeted to lysosomes. This observation is consistent in part with the Int. J. Mol. Sci. 2010, 11              
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notion that both melanosome and neuromelanin are derived from specialized lysosomes [32–34] and 
that the targeting signals for melanosomes and lysosomes are functionally equivalent and 
exchangeable  [35]. Thus, the expressed tyrosinase may be sorted to lysosomes in the established 
neuronal cell lines that lack melanosomes. 
Figure 2. Inducible expression of human tyrosinase in SH-SY5Y cell. 
Immunohistochemical staining of SH-SY5Y cell line expressing tyrosinase under 
tetracycline regulatable promoter. At 72 hrs after the induction with doxycycline (1 g/mL), 
dispersed cytoplasmic tyrosinase protein (green) had accumulated in cytoplasmic particles, 
which were co-localized with rounded, pigmented bodies mimicking the neuromelanin 
granules. Intracellular ROS production was visualized by ROS indicator DCFH2DA  
(green fluorescence). 
 
The expressed tyrosinase in SH-SY5Y cells showed the DOPA oxidase activity but also oxidase 
activity on DA, suggesting that the expressed tyrosinase could catalyze the oxidation of DA. The 
intracellular DA contents measured by HPLC-EC increased significantly after the overnight induction 
of tyrosinase. In parallel with the formation of cytoplasmic pigmented granules, significant increase of 
intracellular melanin, the oxidized products of DOPA and DA, was observed after the tyrosinase 
induction. Thus, intracellular DOPA produced by tyrosinase was not only oxidized to dopaquinone but 
also converted to DA by intrinsic dopa decarboxylase in catecholaminergic cells.   
3. Overexpression of Tyrosinase Induces Neuronal Cell Death via Activation of SAPKs and 
Caspase 3 Apoptosis Pathway 
The oxidative stress generated by tyrosinase induction is likely to involve DA quinones, which are 
well known to be neurotoxic [10,24]. Indeed, tyrosinase induction in SH-SY5Y cells caused cell death, 
as measured by LDH release assay and MTT assay. This result is in good agreement with the previous Int. J. Mol. Sci. 2010, 11              
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reports showing that artificial expression of tyrosinase in non-pigmented cells triggered the cascade of 
melanin synthesis and produced cytotoxic intermediates followed by growth retardation and/or cell 
death [36–38]. Upon tyrosinase induction, cell death occurred in a time dependent manner. We focused 
on the caspase 3 cleavage and activation of the classical MAPK cascades since one major pathway of 
PD-relevant DA neurotoxicity involves the c-Jun N-terminal kinase (JNK). In a detailed time course 
experiment, doxycycline treatment augumented tyrosinase protein expression already after 6 h  
(Figure 3a). Tyrosinase levels continued to rise until a high level was reached between 36 and 72 h 
post-induction. Cleavage of the effector apoptosis caspase 3 consistent with caspase activation became 
first apparent after maximal induction of tyrosinase, and continually increased to the prolonged time 
points beyond 72 h. Involvement of the MAPK pathways in tyrosinase-induced apoptotic signaling 
was determined using phosphor-specific antibodies recognizing activated forms of MAPKs. Basal 
phosphorylation of p44/p42 MAPK was not changed upon tyrosinase induction. In contrast, activation 
of the JNK-c-Jun pathway became detectable after 36 h. The time course of SAPK stimulation was 
similar to caspase 3 cleavage and LDH release. The tyrosinase inhibitor kojic acid and 
4,4’-dihydroxybiphenyl effectively block the JNK-c-Jun activation and subsequent neuronal cell death, 
suggesting that the induction of tyrosinase enzyme specifically causes neurotoxicity in SH-SY5Y  
cells (Figure 3b). 
Figure 3. Tyrosinase induction causes activation of SAPK and caspase-3 pathways.  
(a) Tyrosinase expression was induced for the indicated times with doxycycline. Samples 
were subjected to Western blot analysis and sequentially probed for tyrosinase, 
procaspase-3 and the activated, cleaved form of caspase-3, JNKs, c-Jun and their activated, 
phosphorylated forms, as indicated. Reprobing the blots for ￿β-actin confirmed equal 
loading. (b) Kojic acid and 4,4’-dihydroxybiphenyl significantly block the 
tyrosinase-mediated JNK-c-Jun activation. 
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4. Conclusions 
We have established catecholaminergic neuronal cell lines that express tyrosinase in response to 
doxycycline, an exogeneous inducer. In these cell lines, the overexpressed tyrosinase protein increases 
the content of DA and ROS, followed by the production of melanin pigments, and finally leads to 
apoptotic cell death. Although catechol oxidized metabolites are likely to be toxic, neuromelanin 
formation itself could be protective by converting cytotoxic excess DA to stable neuromelanin. In 
contradiction to our results, it was previously demonstrated that the inhibition of tyrosinase reduced 
cell viability and in catecholaminergic CATH.a cell. This disagreement would be attributed to the 
different types of cells in each study. SH-SY5Y cells used in our study express quite lower level of DA 
at stable state than DA-rich primary mesencephalic neuron or CATH.a cell, indicating that SH-SY5Y 
cell would be more vulnerable against catechol metabolites because of its poor anti-oxidative system.   
It is still controversial whether tyrosinase is involved in the neuromelanin-biosynthetic pathway, 
however, as a model system, this cellular model provides a useful tool for exploring the possible roles 
of catecholamine and its oxidized metabolites or certain environmental factors in the pathogenesis of 
Parkinson’s disease and related neurodegenerative disorders. 
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